American Cancer Society Updates Prostate Cancer Screening Guidelines
Just the facts

American Cancer Society Updates Prostate Cancer Screening Guidelines

Summary

The ACS now advises biennial PSA testing for average-risk men aged 50-69 and annual testing from age 45 for higher-risk groups, adding pathways to limit unnecessary biopsies.

The American Cancer Society released revised prostate cancer screening recommendations, recommending prostate-specific antigen (PSA) testing every two years for average-risk men aged 50 to 69. Men at higher risk, including Black men and non-Black men with a strong family history, should begin annual testing at age 45 and continue through age 69. A single first-degree relative diagnosed after age 65 warrants biennial testing for non-Black men starting at 45.

The guideline introduces a protocol for evaluating elevated PSA levels before biopsy. For men 45 to 69, a PSA of 3.0 ng/mL or higher prompts repeat testing within two weeks to three months, followed by optional MRI or validated biomarker assessment if the elevation persists. For men 70 to 74 who continue screening, the threshold is 6.5 ng/mL.

Screening for men 70 to 74 should be individualized, and routine testing is not advised for those 75 and older or with a life expectancy under ten years. The update also stresses active surveillance as the preferred initial approach for low-risk prostate cancer to avoid overtreatment.

"PSA testing remains the cornerstone of detecting prostate cancer early, and we now have stronger evidence of its benefits," said Robert A. Smith, PhD, senior vice president of early cancer detection science at the ACS.

The ACS estimates that about 333,830 men in the United States will be diagnosed with prostate cancer in 2026, with roughly 36,320 expected deaths, according to its news release. The organization will continue to monitor new evidence and revise the guidelines as needed.

Keep reading — for free

Create a free account to follow the news. No card required.